Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-25-046280
Filing Date
2025-05-08
Accepted
2025-05-08 17:53:02
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 48413
  Complete submission text file 0001104659-25-046280.txt   50269
Mailing Address 1401 FOCH STREET SUITE 140 FORT WORTH TX 76107
Business Address 1401 FOCH STREET SUITE 140 FORT WORTH TX 76107 817-984-5964
BIOS Fund II, LP (Filed by) CIK: 0001714576 (see all company filings)

EIN.: 822436048 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118
Business Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118 (646) 600-6438
IN8BIO, INC. (Subject) CIK: 0001740279 (see all company filings)

EIN.: 825462585 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-92777 | Film No.: 25927648
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)